Kancera

The period in brief – financial summary for the fourth quarter

• Net sales amounted to SEK 0 million (SEK 0).
• R&D expenses amounted to SEK 17,1 million (SEK 11,6 million).
• Operating income amounted to SEK -18,5 million (SEK -14,0 million).
• Income after financial items amounted to SEK -18,5 million (SEK -14,0 million).
• Earnings per share, before and after dilution, amounted to SEK -0.23 (SEK -0.22).
• Cash flow from operating activities amounted to SEK -12,5 million (SEK -9,8 million).

Financial summary for the full year 2023

• Net sales amounted to SEK 0 million (SEK 0).
• R&D expenses amounted to SEK 58,0 million (SEK 45,6 million).
• Operating income amounted to SEK -65,0 million (SEK -51,9 million).
• Income after financial items amounted to SEK -64,9 million (SEK -52,5 million).
• Earnings per share, before and after dilution, amounted to SEK -0.81 (SEK -0.90).
• Cash flow from operating activities amounted to SEK -53,5 million (SEK -48,2 million).
• Equity amounted to SEK 47,7 million (SEK 106,9 million) or SEK 0.58 (SEK 1.34) per share.
• The equity ratio was 73 percent (89 percent).
• Cash and cash equivalents amounted to SEK 45,7 million (SEK 95,1 million).

Significant events during the fourth quarter

• Kancera reported that FIMEA has granted approval to conduct a phase I study of KAND145.
• Kancera reported that the phase I study of KAND145 has started.
• Kancera reported that additional sites have been added to the KANDOVA study and that in total five sites in Sweden, Norway and Denmark are now part of the study.
• Kancera submitted applications to the applicable regulatory authorities and ethical committees in Sweden, Norway and Denmark for modification of the KANDOVA study protocol, with specific regards to the patient inclusion criteria.
• Kancera reported positive top line results from the FRACTAL study.
• Kancera reported that it is exercising its option to obtain the rights to the results from the FRACTAL study from the University of Newcastle.
• Kancera submitted applications to the WHO to obtain non-proprietary names for KAND567 and KAND145.

Important events after the end of the period

• Kancera has reported detailed results from statistical analyses of the FRACTAL study results.
• Kancera has signed a license agreement with the University of Newcastle concerning the exclusive global rights to the results from the FRACTAL study, including a submitted patent application.
• Kancera has received approval of the adjusted KANDOVA study protocol from all regulatory authorities and ethical committees.
• Kancera has completed the first part of the ongoing phase I study of KAND145.
• Kancera announces a planned rights issue.

About Kancera AB (publ)
Kancera is developing a new class of small molecule drugs targeting the fractalkine axis. Kancera’s main focus is to develop its candidate drugs for treatment of severe inflammatory diseases and cancer that currently lack effective treatments. The stock is traded on the Nasdaq First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser.

For further information
Please refer the presentation of the 2023 Q4 Interim Report, available on Kancera’s website: www.kancera.com/en/investor-relations/presentations/

or contact:
Peter Selin
CEO, Kancera AB
peter.selin@kancera.com or phone: +46 (0)8-5012 60 80